These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 7540039)
1. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. de Wit R; Stoter G; Sleijfer DT; Kaye SB; de Mulder PH; ten Bokkel Huinink WW; Spaander PJ; de Pauw M; Sylvester R Br J Cancer; 1995 Jun; 71(6):1311-4. PubMed ID: 7540039 [TBL] [Abstract][Full Text] [Related]
2. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. de Wit R; Stoter G; Sleijfer DT; Neijt JP; ten Bokkel Huinink WW; de Prijck L; Collette L; Sylvester R Br J Cancer; 1998 Sep; 78(6):828-32. PubMed ID: 9743309 [TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363 [TBL] [Abstract][Full Text] [Related]
4. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991 [TBL] [Abstract][Full Text] [Related]
5. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
6. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC; Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625 [TBL] [Abstract][Full Text] [Related]
7. [BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors]. Mori Y; Shima H; Ihara H; Yabumoto H; Iwasaki A; Yoshioka M; Ikoma F Hinyokika Kiyo; 1992 Oct; 38(10):1139-42. PubMed ID: 1282774 [TBL] [Abstract][Full Text] [Related]
8. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ; Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888 [TBL] [Abstract][Full Text] [Related]
9. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193 [TBL] [Abstract][Full Text] [Related]
10. Potential advances in combination chemotherapy for advanced testicular cancer. Kaye SB; Stoter G; Sleijfer D; Jones W; Ten Bokkel Huinink W; Splinter T; Van Oosterom A; Harris A; Boven E; De Pauw M Prog Clin Biol Res; 1988; 269():461-9. PubMed ID: 2455913 [TBL] [Abstract][Full Text] [Related]
11. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of metastatic seminoma by chemotherapy.: an experience]. Komatsubara S; Itoi T; Watanabe M; Kitamura Y; Koike T Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):666-72. PubMed ID: 11109817 [TBL] [Abstract][Full Text] [Related]
13. [Advanced germinal tumors of the testicle: clinical experience with cisplatin, bleomycin and vinblastine (PVB) or etoposide (BEP)]. Alonso Curbera G; González-Manzano R; Aramendía Beitia JM; Martínez Monge R; Agüera Fernández L; Rebollo Liceaga J Rev Med Univ Navarra; 1993; 38(1):13-8. PubMed ID: 8711305 [TBL] [Abstract][Full Text] [Related]
14. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP; J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419 [TBL] [Abstract][Full Text] [Related]
16. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Kawai K; Hinotsu S; Tomobe M; Akaza H Jpn J Clin Oncol; 1998 Sep; 28(9):546-50. PubMed ID: 9793027 [TBL] [Abstract][Full Text] [Related]
17. Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma. Gietema JA; Willemse PH; Mulder NH; Oldhoff J; de Vries EG; Sleijfer DT Eur J Cancer; 1991; 27(11):1376-9. PubMed ID: 1720634 [TBL] [Abstract][Full Text] [Related]
18. Treatment of testicular cancer: a new and improved model. Einhorn LH J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077 [TBL] [Abstract][Full Text] [Related]
19. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204 [TBL] [Abstract][Full Text] [Related]
20. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]